RMTI
Rockwell Medical, Inc. (DE) Common Stock
stockNASDAQ
rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell's new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 7.73 | 2026-11-06 | -9.31% | -1.439 |
| 1M | 7.85 | 2026-10-13 | -10.70% | 0.963 |
| 3M | 7.83 | 2026-08-13 | -10.41% | 0.797 |
| 6M | 8.01 | 2026-05-13 | -12.49% | 0.391 |
| 1Y | 9.13 | 2025-11-13 | -23.18% | 0.516 |
| 2Y | 26.30 | 2024-11-13 | -73.35% | — |
| 5Y | 57.55 | 2021-11-12 | -87.82% | 1.238 |
Rockwell Medical, Inc. (DE) Common Stock (NASDAQ:RMTI) stock price today is $7.01, and today's volume is 42,451. RMTI is down 5.014% today. The 30 day average volume is 27,561. RMTI market cap is $28.25M with 4.03M shares outstanding.